Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Clinical Epidemiology |
Vol/bind | 2 |
Sider (fra-til) | 145-51 |
Antal sider | 7 |
Status | Udgivet - 1 jan. 2010 |
ID: 34052160